KR20210100135A - Esr1 돌연변이를 보유하는 모델에서 암을 치료하기 위한 방법 - Google Patents

Esr1 돌연변이를 보유하는 모델에서 암을 치료하기 위한 방법 Download PDF

Info

Publication number
KR20210100135A
KR20210100135A KR1020217020309A KR20217020309A KR20210100135A KR 20210100135 A KR20210100135 A KR 20210100135A KR 1020217020309 A KR1020217020309 A KR 1020217020309A KR 20217020309 A KR20217020309 A KR 20217020309A KR 20210100135 A KR20210100135 A KR 20210100135A
Authority
KR
South Korea
Prior art keywords
elastrant
subject
cancer
dose
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217020309A
Other languages
English (en)
Korean (ko)
Inventor
히티샤 파텔
테루 비하니
헤이케 알트
니안준 타오
Original Assignee
래디어스 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 래디어스 파마슈티컬스, 인코포레이티드 filed Critical 래디어스 파마슈티컬스, 인코포레이티드
Publication of KR20210100135A publication Critical patent/KR20210100135A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217020309A 2018-12-06 2019-12-06 Esr1 돌연변이를 보유하는 모델에서 암을 치료하기 위한 방법 Ceased KR20210100135A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
US62/776,338 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Publications (1)

Publication Number Publication Date
KR20210100135A true KR20210100135A (ko) 2021-08-13

Family

ID=69158304

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217020309A Ceased KR20210100135A (ko) 2018-12-06 2019-12-06 Esr1 돌연변이를 보유하는 모델에서 암을 치료하기 위한 방법

Country Status (17)

Country Link
US (2) US20220016052A1 (enExample)
EP (1) EP3890835A1 (enExample)
JP (2) JP7497353B2 (enExample)
KR (1) KR20210100135A (enExample)
AU (1) AU2019392908B2 (enExample)
BR (1) BR112021010141A2 (enExample)
CA (1) CA3121918A1 (enExample)
EA (1) EA202191256A1 (enExample)
IL (1) IL283655A (enExample)
JO (1) JOP20210138A1 (enExample)
MA (1) MA54393A (enExample)
MX (1) MX2021006412A (enExample)
MY (1) MY208702A (enExample)
PH (1) PH12021551327A1 (enExample)
SG (1) SG11202105915UA (enExample)
UA (1) UA129588C2 (enExample)
WO (1) WO2020118202A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3122426T3 (pl) * 2014-03-28 2023-05-15 Duke University Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
WO2016176665A1 (en) * 2015-04-29 2016-11-03 Radius Health, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
JOP20210138A1 (ar) 2023-01-30
US20250241875A1 (en) 2025-07-31
MA54393A (fr) 2021-10-13
UA129588C2 (uk) 2025-06-11
JP2024101017A (ja) 2024-07-26
PH12021551327A1 (en) 2022-04-25
JP7497353B2 (ja) 2024-06-10
IL283655A (en) 2021-07-29
WO2020118202A1 (en) 2020-06-11
BR112021010141A2 (pt) 2021-08-24
AU2019392908B2 (en) 2025-02-20
US20220016052A1 (en) 2022-01-20
SG11202105915UA (en) 2021-07-29
EA202191256A1 (ru) 2021-10-06
MY208702A (en) 2025-05-25
AU2019392908A1 (en) 2021-06-10
EP3890835A1 (en) 2021-10-13
MX2021006412A (es) 2021-07-21
CA3121918A1 (en) 2020-06-11
JP2022511497A (ja) 2022-01-31

Similar Documents

Publication Publication Date Title
JP7516472B2 (ja) 癌を治療するための方法
US20250319044A1 (en) Methods for treating cancer resistant to cdk4/6 inhibitors
KR20210097170A (ko) 유방암을 갖는 여성에서 아베마시클립과 조합된 엘라세스트란트
US20250241875A1 (en) Methods for treating cancer in models harboring esr1 mutations
RU2822195C2 (ru) Способы лечения рака на моделях, имеющих мутации esr1
EA046925B1 (ru) Способы лечения рака на моделях, имеющих мутации esr1
RU2820478C2 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
EA047283B1 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
HK40079056A (en) Methods of treating cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601